Synribo is owned by Teva Pharms Intl.
Synribo contains Omacetaxine Mepesuccinate.
Synribo has a total of 1 drug patent out of which 0 drug patents have expired.
Synribo was authorised for market use on 26 October, 2012.
Synribo is available in powder;subcutaneous dosage forms.
Synribo can be used as treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml).
The generics of Synribo are possible to be released after 26 October, 2026.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6987103||TEVA PHARMS INTL||Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents|| |
(3 years from now)
Market Authorisation Date: 26 October, 2012
Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml)
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic